A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.
about
Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetronManagement of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant-palonosetron combinationProphylactic Management of Radiation-Induced Nausea and VomitingA Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and VomitingThe First Oral Fixed-Dose Combination of Netupitant and Palonosetron for the Treatment of Chemotherapy-Induced Nausea and VomitingNeurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: a network meta-analysisRecent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive reviewDrug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical dataDelayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current ManagementSafety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trialNetupitant PET imaging and ADME studies in humans.Neuropharmacology and management of chemotherapy-induced nausea and vomiting in patients with breast cancer.Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence.Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)Aprepitant and fosaprepitant: a 10-year review of efficacy and safetyIntegrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily.Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trialsPrevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparisonComparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients.Netupitant/Palonosetron.Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy.NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK.Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists.Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting.Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.The role of netupitant and palonosetron in chemotherapy-induced nausea and vomiting.Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy.Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting.State of the Art Antiemetic Therapy for Cancer Patients.The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.Rolapitant: a pooled analysis of its efficacy and safety in the prophylaxis of chemotherapy-induced nausea and vomiting.Rolapitant for the prevention of delayed nausea and vomiting over initial and repeat courses of emetogenic chemotherapy.Helsinn: 20 years in primary cancer supportive care.2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy.
P2860
Q26746211-0732D368-0938-483C-8FA8-DED60865B102Q26748524-274D3E21-18CA-40EF-B712-3C679A308A1FQ26783184-1C996F6F-E1A4-4ACA-998A-DA8C68A9A7E2Q26784064-7835A912-CBD7-4D16-A165-5DBD35046512Q28072596-C60DE7A1-C8CD-406C-B9B7-E10EE5EFFE56Q28078513-C3EF59C0-78AF-4892-BF18-19CF27700DC8Q28081186-677F00CE-6E85-43DB-8AA3-6D1D2D37AE03Q28084970-4533170B-B5C3-4B33-9385-2BEE6C053C5FQ30235971-F6767B2C-8291-4770-9F87-90BACB81E750Q31061449-11596219-9B77-4107-9A4F-B656DB33ED35Q33809590-96E5AB0A-2556-4481-8E79-1D154DA62D52Q34011870-1E57280F-2329-4B27-896C-6FC5AFFD4B72Q34377521-28E0848F-8BC6-47D0-AFEF-D258D62D991CQ34403552-FA4B7453-0549-4B82-9175-81F129443A43Q34512212-FBA5170F-A209-432A-9072-00C3C5FE5AF0Q34775395-22DFCD84-042A-4E2F-9B51-D36B90330AE4Q35345557-B113FF1E-C58C-4870-B5AF-BB3A9713A3D8Q35671396-359BD783-29AB-44CF-8A35-621148F8FE83Q35789229-B059DC45-A293-4889-97B7-077398583774Q35970506-4B3B7886-A1C3-4975-BEFC-1345C6CE84DCQ36093627-907EF290-733F-445B-BCEA-0B72D6147782Q36110050-62C34E65-2061-44C6-94DE-97115AEB911DQ36384479-665D0F9F-8F40-40BD-BF06-F0F312E37BCFQ37606033-7DFE7810-D408-419B-AC99-666D46607942Q37660556-51D75CE8-F750-448B-B6B2-5F6BF054762EQ37730595-4534A0A1-9709-49D7-AA69-4BC2C51C1D71Q37735410-F73C7109-3EA7-455D-BBAA-88C676B29320Q37736060-AE94E284-C74F-4D18-BCCA-C8AF700FB1E7Q38250191-075DE652-529F-43DF-B3D5-FB4D376D04B1Q38264147-A464A988-D828-47D8-8341-818499BEFECCQ38443441-C56E1036-AC73-4F0E-B1BE-D1EEF1DCCEC8Q38574240-1287F25C-A098-43EE-A43B-4589B427DCC4Q38648133-CF5A4BD0-B2CE-40E2-9141-564B244AC9CCQ38650400-518FE84C-B0D3-469C-948A-466EB3F5D566Q38676452-82B5E80E-74DA-4B0B-8ADE-6A7C34F44DACQ38677762-BFA32758-F28F-4EEF-8362-C6E883F7E7C3Q38710356-5D8D12AD-A3DC-4A51-88B7-0E87789FD12DQ38789806-23542324-864B-4145-8068-BABD051E7D29Q38815897-77A141AB-E1AD-4F1C-B406-12EE8EED6B3DQ38904462-29A358A7-8204-4F42-A48C-7FE5B4838402
P2860
A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
A phase III study evaluating t ...... peated cycles of chemotherapy.
@ast
A phase III study evaluating t ...... peated cycles of chemotherapy.
@en
type
label
A phase III study evaluating t ...... peated cycles of chemotherapy.
@ast
A phase III study evaluating t ...... peated cycles of chemotherapy.
@en
prefLabel
A phase III study evaluating t ...... peated cycles of chemotherapy.
@ast
A phase III study evaluating t ...... peated cycles of chemotherapy.
@en
P2093
P2860
P356
P1433
P1476
A phase III study evaluating t ...... peated cycles of chemotherapy.
@en
P2093
M E Borroni
R J Gralla
S M Bosnjak
P2860
P304
P356
10.1093/ANNONC/MDU096
P577
2014-03-14T00:00:00Z